Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

PHASE3RecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions
Relapsing Multiple Sclerosis
Interventions
BIOLOGICAL

Ublituximab

Administered as an intravenous (IV) infusion.

DRUG

Placebo

IV infusion

Trial Locations (46)

10025

RECRUITING

TG Therapeutics Investigational Trial Site, New York

11021

RECRUITING

TG Therapeutics Investigational Trial Site, New York

20007

RECRUITING

TG Therapeutics Investigational Trial Site, Washington D.C.

21093

RECRUITING

TG Therapeutics Investigational Trial Site, Lutherville

22182

RECRUITING

TG Therapeutics Investigational Trial Site, Vienna

27607

RECRUITING

TG Therapeutics Investigational Trial Site, Raleigh

28204

RECRUITING

TG Therapeutics Investigational Trial SiteCharlotte, Charlotte

29605

RECRUITING

TG Therapeutics Investigational Trial Site, Greenville

33612

RECRUITING

TG Therapeutics Investigational Trial Site, Tampa

35058

RECRUITING

TG Therapeutics Investigational Trial Site, Cullman

35209

RECRUITING

TG Therapeutics Investigational Trial Site, Birmingham

37922

RECRUITING

TG Therapeutics Investigational Trial Site, Knoxville

44195

RECRUITING

TG Therapeutics Investigational Trial Site, Cleveland

45417

RECRUITING

TG Therapeutics Investigational Trial Site, Dayton

46256

RECRUITING

TG Therapeutics Investigational Trial Site, Indianapolis

48334

RECRUITING

TG Investigational Site, Farmington

52242

RECRUITING

TG Therapeutics Investigational Trial Site, Iowa City

53226

RECRUITING

TG Therapeutics Investigational Trial Site, Milwaukee

55422

RECRUITING

TG Therapeutics Investigational Trial Site, Golden Valley

55446

RECRUITING

TG Therapeutics Investigational Trial Site, Plymouth

60612

RECRUITING

TG Therapeutics Investigational Trial Site, Chicago

63131

RECRUITING

TG Therapeutics Investigational Trial Site, St Louis

66212

RECRUITING

TG Therapeutics Investigational Trial Site, Overland Park

73104

RECRUITING

TG Therapeutics Investigational Trial Site, Oklahoma City

77030

RECRUITING

TG Therapeutics Investigational Trial Site, Waco

80528

RECRUITING

TG Investigational Site, Fort Collins

84103

RECRUITING

TG Therapeutics Investigational Trial Site, Salt Lake City

92697

RECRUITING

TG Therapeutics Investigational Trial Site, Orange

98034

RECRUITING

TG Therapeutics Investigational Trial Site, Kirkland

98109

RECRUITING

TG Therapeutics Investigational Trial Site, Seattle

99208

RECRUITING

TG Therapeutics Investigational Trial Site, Spokane

00002

RECRUITING

TG Therapeutics Investigational Trial Site, Boston

02035

RECRUITING

TG Therapeutics Investigational Trial Site, Foxborough

01655

RECRUITING

TG Therapeutics Investigational Trial Site, North Worcester

02481uni

RECRUITING

TG Therapeutics Investigational Trial Site, Wellesley

Unknown

RECRUITING

TG Therapeutics Investigational Trial Site, Bydgoszcz

RECRUITING

TG Therapeutics Investigational Trial Site, Katowice

RECRUITING

TG Therapeutics Investigational Trial Site, Kielce

RECRUITING

TG Therapeutics Investigational Trial Site, Lodz

RECRUITING

TG Therapeutics Investigational Trial Site, Poznan

RECRUITING

TG Therapeutics Investigational Trial Site, Zabrze

40-555

RECRUITING

TG Therapeutics Investigational Trial Site, Katowice

31-826

RECRUITING

TG Therapeutics Investigational Trial Site, Krakow

10-561

RECRUITING

TG Therapeutics Investigational Trial Site, Olsztyn

04-141

RECRUITING

TG Therapeutics Investigational Trial Site, Warsaw

44-240

RECRUITING

TG Therapeutics Investigational Trial Site, Żory

All Listed Sponsors
lead

TG Therapeutics, Inc.

INDUSTRY

NCT05877963 - Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | Biotech Hunter | Biotech Hunter